NORTHBROOK, Ill., Sept. 12, 2016 /PRNewswire/ -- Astellas today announced the five C3 Prize finalists chosen to present their ideas live at the Stanford Medicine X conference on Sept. 17 to a panel of judges including Robert Herjavec, dynamic entrepreneur, passionate cancer caregiver and star of ABC's Emmy Award-winning television show, Shark Tank. The C3 Prize is a challenge designed to inspire non-medicine innovations to improve the cancer care experience for patients, caregivers and their loved ones.
"The power of technology is driving dramatic advances for cancer patients, but more remains to be done for people with cancer and their loved ones outside of clinical treatment," said Herjavec. "The Astellas C3 Prize harnesses this momentum by rallying health care advocates from around the world to bring non-treatment based innovation in cancer care to reality."
Herjavec's experience caring for his mother, who died of ovarian cancer in 2007, drove his choice to partner with Astellas Oncology as a judge for the C3 Prize. "I know, from personal experience, the daily challenges faced by those affected by cancer. I also know, from professional experience, the power and impact technology can make on improving lives. The five C3 Prize finalists represent this intersection of personal connection, creativity and tenacity."
The C3 Prize solicited submissions in four areas where patients living with cancer and the cancer community face obstacles: navigating the health care system, adhering to complex medical care requirements, coordinating care and surviving life post-treatment.
More than 100 patients, caregivers, healthcare providers and technology entrepreneurs from around the world submitted innovations to potentially change cancer care. The five finalists are:
"The complexity of navigating cancer care beyond treatment itself is staggering," said Mark Reisenauer, senior vice president, Oncology, Astellas, whose experience caring for his late father influenced the development and launch of the C3 Prize. "We are thrilled with the volume and sophistication of the submissions we received. Each of the five finalist innovations represents a tremendous opportunity to improve patient and caregiver lives. This is what drives the Astellas Oncology team every day."
Reisenauer will be a member of the judging panel, alongside Herjavec. Chris Coburn, vice president, innovation at Partners HealthCare and Michael Seres, ePatient-in-Residence, Stanford Medicine X, will also serve as judges.
Based on the judges' selections, Astellas Oncology will award three winners a total of $100,000 in grants to advance their idea, along with mentorship and access to MATTER, a community of entrepreneurs, innovators and industry leaders working together to improve health and health care.
A live stream of the finalist presentations on Sept. 17 can be viewed at medxlive.stanford.edu from 12:40 p.m. – 2:10 p.m. Pacific Daylight Time.
For more information, visit www.C3Prize.com.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
About Stanford Medicine X
Stanford Medicine X is a catalyst for new ideas about the future of medicine and health care. The initiative explores how emerging technologies will advance the practice of medicine, improve health and empower patients to be active participants in their own care. The "X" is meant to encourage thinking beyond numbers and trends — it represents the infinite possibilities for current and future information technologies to improve health. For more information about Medicine X, visit medicinex.stanford.edu.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-oncology-selects-five-c3-prize-finalists-to-pitch-ideas-for-changing-cancer-care-to-panel-including-robert-herjavec-at-stanford-medicine-x-300325931.html
SOURCE Astellas Pharma Inc.